IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`IN RE: SITAGLIPTIN PHOSPHATE (’708
`& ’921) PATENT LITIGATION
`
`MDL No. 19-2902-RGA
`
`C.A. Nos. 19-310-RGA,
`19-311-RGA,
`19-312-RGA,
`19-313-RGA,
`19-314-RGA,
`19-316-RGA,
`19-317-RGA,
`19-318-RGA,
`19-319-RGA,
`19-320-RGA,
`19-321-RGA,
`19-347-RGA,
`19-872-RGA,
`19-1489-RGA
`
`PLAINTIFF MERCK SHARP & DOHME CORP.’S
`RESPONSES AND OBJECTIONS TO DEFENDANTS’
`FIRST SET OF JOINT INTERROGATORIES (NOS. 1–10)
`
`Pursuant to Rules 26 and 33 of the Federal Rules of Civil Procedure, Plaintiff Merck
`
`Sharp & Dohme Corp. (“Merck”), by undersigned counsel, hereby objects and responds as
`
`follows to Defendants’ First Set of Joint Interrogatories.
`
`GENERAL OBJECTIONS
`
`Pursuant to D. Del. LR 26.1, Merck provides the following General Objections. These
`
`objections form a part of, and are hereby incorporated into, the response to each and every
`
`interrogatory set forth below. Nothing in those responses, including any failure to recite a
`
`specific objection in response to a particular interrogatory, should be construed as a waiver of
`
`any of these General Objections.
`
`1.
`
`Merck objects to each interrogatory, definition, and instruction to the extent that it
`
`purports to impose obligations or responsibilities different from or in excess of those imposed by
`
`ME1 31736116v.1
`
`1
`
`1 of 26
`
`IPR2020-01045
`Teva Ex. 1015
`
`

`

`
`
`the Federal Rules of Civil Procedure and the Local Rules of the United States District Court for
`
`the District of Delaware, or any other applicable rule, law, doctrine or accepted practice. Merck
`
`will interpret and respond to the interrogatories in good faith and in accordance with the rules.
`
`2.
`
`Merck objects to each interrogatory, definition, and instruction to the extent that it
`
`calls for the disclosure of information or documents that are privileged or otherwise protected
`
`from discovery pursuant to the attorney-client privilege, the accountant-client privilege, the
`
`common-interest privilege, the work product doctrine, or any other applicable privilege,
`
`protection, or immunity. Merck does not agree to provide such information or documents
`
`protected from discovery and will withhold or redact information or documents on that basis. If
`
`protected information or documents are inadvertently provided in response to the interrogatories,
`
`pursuant to the parties’ Stipulated Protective Order, D.I. 12, No. 19-md-2902-RGA, and Federal
`
`Rule of Evidence 502, the production of such information or documents shall not constitute a
`
`waiver of Merck’s rights to assert the applicability of any privilege, protection, or immunity to
`
`the information or documents, to seek the return of such material, or to object to the use of such
`
`material at any stage of the action or in any other action or proceeding. Merck will comply with
`
`the Federal Rules of Civil Procedure and the Local Rules of the United States District Court for
`
`the District of Delaware in identifying privileged material, but Merck specifically objects to
`
`identifying on a privilege log communications between Merck and its litigation counsel, or
`
`documents or electronically stored information that were created after December 13, 2010, which
`
`was the date of the first Patent Certification Notice pursuant to Section 505(j)(2)(B)(ii) of the
`
`Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j)(2)(B)(ii), received by Merck
`
`indicating that a generic pharmaceutical company intended to market a sitagliptin product before
`
`the expiry of patents protecting Januvia®, Janumet®, Janumet® XR, and will not log such
`
`ME1 31736116v.1
`
`2
`
`2 of 26
`
`IPR2020-01045
`Teva Ex. 1015
`
`

`

`
`
`documents. Merck further objects to logging documents or electronically stored information
`
`related to other United States or foreign litigations, as well as documents or electronically stored
`
`information related to foreign patent office proceedings or foreign regulatory filings or
`
`approvals, on the grounds that such materials are not relevant to the subject matter of this
`
`litigation and that logging them would be unduly burdensome, and will not log such documents
`
`or electronically stored information.
`
`3.
`
`Merck objects to Defendants’ Instruction No. 10 to the extent that it requires
`
`logging of more information than required by the Federal Rules of Civil Procedure, the Local
`
`Rules of the United States District Court for the District of Delaware, or any other applicable
`
`rules. Merck will comply and identify privileged material in a manner consistent with the
`
`foregoing rules.
`
`4.
`
`Merck objects to Defendants’ requests to the extent that they call for disclosure of
`
`trade secret, proprietary, personal, commercially sensitive, third-party confidential, or other
`
`confidential information. Merck will only disclose confidential information, including trade
`
`secret, proprietary, personal, commercially sensitive, third-party confidential, or other
`
`confidential information, that is responsive, relevant, and not otherwise protected, pursuant to the
`
`stipulated protective order, D.I. 12, No. 19-md-2902-RGA, and/or D. Del. LR 26.2. Merck may
`
`withhold information or documents on this basis, and Merck may redact confidential information
`
`from documents that it has otherwise agreed to produce.
`
`5.
`
`Merck may, in response to certain of Defendants’ interrogatories, refer to or
`
`produce documents from custodians or non-custodial sources located outside the United States.
`
`Foreign privacy laws, over which Merck has no control, may have a substantial impact on the
`
`nature and extent of information or documents that Merck can disclose or produce from such
`
`ME1 31736116v.1
`
`3
`
`3 of 26
`
`IPR2020-01045
`Teva Ex. 1015
`
`

`

`
`
`sources. Merck objects to the interrogatories to the extent that they call for production of
`
`information from any jurisdiction outside that United States that (i) pertains to a specific
`
`individual that can be linked to that individual; or (ii) is reasonably believed by Merck to contain
`
`information about or pertaining to a specific individual that can be linked to that individual and
`
`that reveals race, ethnic origin, sexual orientation, political opinions, religious or philosophical
`
`beliefs, trade union or political party membership or that concerns an individual’s health. Merck
`
`is withholding such documents or information on this basis and will redact such information
`
`from any documents that it produces in this action.
`
`6.
`
`Merck objects to each interrogatory, definition, and instruction to the extent that it
`
`seeks “any” or “all” information responsive to the interrogatory. Such demands are unduly
`
`burdensome and overly broad, and they seek documents that are not relevant to the claim or
`
`defense of any party or proportional to the needs of the case considering the importance of the
`
`issues at stake in the action, the amount in controversy, the parties’ relative access to relevant
`
`information, the parties’ resources, the importance of the discovery in resolving the issues, and
`
`whether the burden or expense of the proposed discovery outweighs its likely benefit. Merck’s
`
`search for responsive information will be limited to the non-custodial sources and custodians
`
`identified by Merck, agreed to by the parties, or ordered by the Court. Absent such agreement or
`
`order, Merck will not search for or produce documents from any other source or location.
`
`Additionally, Merck incorporates by reference all objections set forth in the General Objections
`
`of Merck’s Responses and Objections to Defendants’ First Set of Joint Requests for the
`
`Production of Documents and Things to Plaintiff (Nos. 1–107), which are incorporated herein by
`
`reference, and will not search for or produce documents created outside of the date restrictions
`
`set forth therein.
`
`ME1 31736116v.1
`
`4
`
`4 of 26
`
`IPR2020-01045
`Teva Ex. 1015
`
`

`

`
`
`7.
`
`Merck objects to each interrogatory, definition, and instruction as overly broad
`
`and unduly burdensome to the extent that it purports to require Merck to search for and produce
`
`electronic documents without reasonable limitations upon the scope of information to be
`
`searched or the content of the material to be searched for. Merck will use reasonable diligence to
`
`respond to the interrogatories based on information and/or documents in its possession, custody,
`
`or control, based on a reasonable search of those files that are reasonably accessible and in which
`
`such information or documents ordinarily would be found and of files of those individuals whom
`
`Merck reasonably believes are most likely to have responsive documents and/or information
`
`about the specific matters at issue.
`
`8.
`
`Merck objects to each interrogatory, definition, and instruction to the extent that it
`
`seeks information that is unreasonably cumulative or duplicative, that is publicly available, that
`
`is already known to Defendants or Defendants’ counsel, that is of no greater burden for
`
`Defendants to ascertain than Merck, or that is ascertainable from some other source that is more
`
`convenient, less burdensome, or less expensive, that is otherwise more appropriately obtained
`
`from another party, and/or to the extent that compliance would be unduly burdensome,
`
`expensive, or oppressive. Unless otherwise indicated specifically below, Merck will not provide
`
`any such information or documents.
`
`9.
`
`Merck objects to each interrogatory incorporating or calling for a subjective
`
`judgment that information “concerns” a particular issue, “supports” a particular issue, or
`
`“refutes” a particular issue. By their subjective nature, such interrogatories are vague and
`
`ambiguous. Such interrogatories also intrude upon the attorney-work product protection by
`
`seeking an identification of the information that counsel considers relevant to a particular issue.
`
`To the extent that such interrogatories seek “all” information, they also are overly broad and
`
`ME1 31736116v.1
`
`5
`
`5 of 26
`
`IPR2020-01045
`Teva Ex. 1015
`
`

`

`
`
`unduly burdensome because they fail to account for proportionality. Merck will consider as
`
`responsive to any request that seeks documents or things “concerning,” “reflecting,” “regarding,”
`
`or “relating” (or similar language) to a designated subject only those documents or things that
`
`discuss the subject on their face.
`
`10. Merck objects to each interrogatory, definition, and instruction incorporating or
`
`calling for a legal conclusion or premised on an erroneous statement of law. By incorporating
`
`the need to make a legal conclusion or erroneous statement of law, such interrogatories are vague
`
`and ambiguous. Such interrogatories also intrude upon the attorney-work product protection by
`
`seeking an identification of the information that counsel believes satisfy the legal contention. To
`
`the extent that such interrogatories seek “all” documents, they also are overly broad and unduly
`
`burdensome because they fail to account for proportionality.
`
`11.
`
`In furnishing these objections and responses to the interrogatories, Merck does not
`
`admit or concede the relevance, materiality, authenticity, or admissibility in evidence of any
`
`interrogatory or information. All objections to the use, at trial or otherwise, of any information
`
`provided in response to the interrogatories and to any further disclosure of information are
`
`hereby expressly reserved. In addition, Merck’s statements that it will produce documents or
`
`things in response to a particular request do not constitute an admission that it has any such
`
`documents, and its responses should not be construed in such a manner. Where Merck responds
`
`that it will produce documents, it means that it will produce those documents that exist and are
`
`located after a reasonable search, subject to Merck’s objections set forth in the General
`
`Objections of Merck’s Responses and Objections to Defendants’ First Set of Joint Requests for
`
`the Production of Documents and Things to Plaintiff (Nos. 1–107), which are incorporated
`
`herein by reference. Unless indicated otherwise, where Merck has agreed to produce documents
`
`ME1 31736116v.1
`
`6
`
`6 of 26
`
`IPR2020-01045
`Teva Ex. 1015
`
`

`

`
`
`in response to particular interrogatories, those documents will be produced on a rolling basis and
`
`in accordance with the Court’s scheduling order.
`
`12. Merck objects to each interrogatory, definition, or instruction to the extent that it
`
`seeks production of documents and electronically stored information relating to Merck’s
`
`sitagliptin products in countries other than the United States—including but not limited to
`
`documents and electronically stored information relating to foreign counterparts to U.S. Patent
`
`Nos. 7,326,708 and 8,414,921 (including any foreign litigation involving such patents), foreign
`
`regulatory documents, and foreign sales and marketing information—on the grounds that such
`
`interrogatories are overly broad, unduly burdensome, and seek information not relevant to any
`
`party’s claim or defense nor proportional to the needs of the case in accordance with Federal
`
`Rule of Civil Procedure 26(b)(1). Merck will not produce such documents and electronically
`
`stored information, and Merck’s responses should be read to exclude the production of such
`
`documents and electronically stored information.
`
`13. Merck objects to each interrogatory, definition, or instruction to the extent it calls
`
`for the production of draft articles, submissions, publications, or other documents, on the ground
`
`and to the extent that production of drafts of documents is unduly burdensome and not relevant
`
`to any party’s claim or defense nor proportional to the needs of the case in accordance with
`
`Federal Rule of Civil Procedure 26(b)(1).
`
`14. Merck objects to each interrogatory, definition, and instruction to the extent that it
`
`prematurely seeks production of information to be provided during expert discovery. Merck will
`
`not prematurely produce documents or information that are to be provided during expert
`
`discovery, and will only produce such documents and information in accordance with the Court’s
`
`schedule for expert discovery.
`
`ME1 31736116v.1
`
`7
`
`7 of 26
`
`IPR2020-01045
`Teva Ex. 1015
`
`

`

`
`
`15. Merck’s responses herein are based on facts presently known to Merck and
`
`represent a diligent and good-faith effort to respond to the interrogatories. Merck’s discovery
`
`and investigation into the matters specified are ongoing. Accordingly, Merck reserves the right
`
`to supplement, alter, or change its responses and objections and to produce additional responsive
`
`information or documents, if any, that Merck has in its possession, custody, or control at the time
`
`the interrogatories were propounded. Furthermore, Merck reserves the right, at trial or during
`
`other proceedings in this action, to rely on documents, evidence, and other matters in addition to
`
`the documents or information produced in response to the interrogatories, whether or not such
`
`documents, evidence, or other matters are newly discovered or are now in existence but have not
`
`been identified or produced despite diligent and good-faith efforts.
`
`16. Merck objects to Defendants’ definition of “Plaintiff,” “Merck” and “You” as
`
`overly broad to the extent that they refer to “any predecessor or successor company” or to the
`
`“present and former principals, partners, directors, owners, officers, members, employees,
`
`agents, representatives, consultants, and attorneys of Merck, or any affiliated corporation or
`
`business entity controlled by Merck.” Documents and electronically stored information in the
`
`possession, custody, or control of Merck’s “present and former principals, partners, directors,
`
`owners, officers, members, employees, agents, representatives, consultants, and attorneys of
`
`Merck, or any affiliated corporation or business entity controlled by Merck” are not necessarily
`
`in the possession, custody, or control of Merck, and Merck will not construe the requests to
`
`require production of such documents or electronically stored information to the extent that they
`
`are not in the possession, custody, or control of Merck. Merck will interpret all references to
`
`“Merck,” “Plaintiff,” and “You” to mean Merck Sharp & Dohme Corp.
`
`ME1 31736116v.1
`
`8
`
`8 of 26
`
`IPR2020-01045
`Teva Ex. 1015
`
`

`

`
`
`17. Merck incorporates by reference all objections set forth in the General Objections
`
`of Merck’s Responses and Objections to Defendants’ First Set of Joint Requests for the
`
`Production of Documents and Things to Plaintiff (Nos. 1–107).
`
`Merck expressly reserves the right to supplement these General Objections.
`
`RESPONSES AND OBJECTIONS TO SPECIFIC INTERROGATORIES
`
`INTERROGATORY NO. 1:
`
`Separately for each asserted claim of the Patents-in-Suit, describe in detail the facts and
`circumstances surrounding the conception and reduction to practice (if any) of the claimed
`subject matter. This description should include, without limitation, the alleged dates and
`locations of any such conception and reduction to practice, including any acts of diligence, the
`identity of each individual involved in the alleged conception or reduction to practice and each of
`their respective roles, and identification of any documents and/or other evidence (including but
`not limited to all communications, invention disclosure forms, and laboratory notebooks) that
`describe the foregoing.
`
`RESPONSE TO INTERROGATORY NO. 1:
`
`Merck incorporates its General Objections as though fully set forth herein. Merck objects
`
`to this interrogatory on the grounds that it is unduly burdensome and overly broad; for example,
`
`the request the Merck identify “any documents” and “all communications” is not a reasonable or
`
`proportionate interrogatory. Merck further objects to this interrogatory as overly broad,
`
`burdensome, vague, and ambiguous with respect to Defendants’ request for “the facts and
`
`circumstances surrounding the conception and reduction to practice . . . of the claimed subject
`
`matter,” and that the information sought by this interrogatory may be more readily ascertainable
`
`from other forms of discovery, including deposition testimony. Merck further objects to this
`
`interrogatory on the basis that it does not seek information relevant to any claim or defense in
`
`this case, particularly in view of the fact that Defendants have not asserted any defense regarding
`
`the conception or reduction to practice of the Patents-in-Suit. Merck further objects to this
`
`interrogatory on the grounds that it contains multiple discrete subparts within the meaning of
`
`ME1 31736116v.1
`
`9
`
`9 of 26
`
`IPR2020-01045
`Teva Ex. 1015
`
`

`

`
`
`Federal Rule of Civil Procedure 33(a)(1) and therefore constitutes multiple interrogatories as
`
`follows. First, there are two Patents-in-Suit with more than twenty asserted claims. As reflected
`
`by Defendants’ request that Merck respond “[s]eparately for each asserted claim,” this
`
`interrogatory in fact contains dozens of interrogatories, far in excess of the fifteen joint
`
`interrogatories permitted to Defendants under the Court’s scheduling orders. Second, this
`
`interrogatory contains at least three subparts seeking (1) a narrative of facts concerning
`
`conception and reduction to practice, (2) an identification of persons with discoverable
`
`information, and (3) an identification of discoverable documents. Merck further objects to this
`
`interrogatory to the extent it seeks information protected by the attorney-client privilege,
`
`attorney-work product doctrine, the common interest privilege, and/or any other applicable
`
`privilege or immunity. Merck objects to this interrogatory because it calls for subjective
`
`relevance determinations concerning persons with discoverable information and/or discoverable
`
`documents.
`
`Subject to and without waiving the foregoing specific and general objections, Merck
`
`states as follows:
`
`The asserted claims of the ’708 patent were conceived of and reduced to practice no later
`
`than the June 24, 2003 filing date of U.S. provisional application No. 60/482,161, and that at
`
`least claims 1 and 2 of the ’708 patent were conceived of and reduced to practice no later than
`
`December 13, 2001.
`
`The asserted claims of the ’921 patent were conceived of and reduced to practice no later
`
`than the December 16, 2005 filing date of U.S. provisional application No. 60/750,954.
`
`Discovery in this matter is ongoing, and Merck is continuing to investigate whether it
`
`will contend that one or more of the claims in any of the Patents-in-Suit was conceived of and
`
`ME1 31736116v.1
`
`10
`
`10 of 26
`
`IPR2020-01045
`Teva Ex. 1015
`
`

`

`
`
`reduced to practice on an earlier date. Merck expressly reserves the right to supplement this
`
`interrogatory response.
`
`Merck further states that, based on the facts presently known to Merck, each of the
`
`inventors listed on the face of the Patents-in-Suit contributed to the conception and reduction to
`
`practice of one or more of the claims of the Patents-in-Suit.
`
`Merck further states that additional information sought by this interrogatory can be
`
`derived or ascertained from documents that Merck will produce subject to Merck’s objections
`
`and responses herein, as well as documents that Merck will produce in response to Defendants’
`
`First Set of Joint Requests for Production of Documents and Things to Plaintiff (Nos. 1–107),
`
`subject to Merck’s objections and responses thereto. Merck will continue to supplement this
`
`interrogatory response in conjunction with the production of such documents.
`
`INTERROGATORY NO. 2:
`
`If Merck contends that any claim of the Patents-in-Suit is entitled to a priority date earlier
`than the filing date of the Patents-in-Suit, identify the earliest priority date to which that claim
`allegedly is entitled, all facts and documents that support or are related to those dates, and the
`three individuals employed by Merck who are most knowledgeable about the subject matter of
`this interrogatory.
`
`RESPONSE TO INTERROGATORY NO. 2:
`
`Merck incorporates its General Objections as though fully set forth herein. Merck objects
`
`to this interrogatory on the grounds that it is unduly burdensome and overly broad; for example,
`
`the request to identify “all facts and documents” is not a reasonable or proportionate
`
`interrogatory. Merck further objects to this interrogatory on the basis that it does not seek
`
`information relevant to any claim or defense in this case, particularly in view of the fact that
`
`Defendants have not asserted any defense regarding the priority date of the asserted claims of the
`
`Patents-in-Suit. Merck further objects to this interrogatory as vague and ambiguous as there are
`
`two Patents-in-Suit with different filing dates, and whether particular facts and documents
`
`ME1 31736116v.1
`
`11
`
`11 of 26
`
`IPR2020-01045
`Teva Ex. 1015
`
`

`

`
`
`“support or are related” to Merck’s contentions requires a subjective determination that intrudes
`
`upon the attorney-work product protection. This interrogatory is further vague and ambiguous
`
`and improperly assumes facts insofar as it seeks the identity of “the three individuals employed
`
`by Merck who are most knowledgeable about the subject matter of this interrogatory.” Merck
`
`further objects to this interrogatory on the grounds that it contains multiple discrete subparts
`
`within the meaning of Federal Rule of Civil Procedure 33(a)(1) and therefore constitutes
`
`multiple interrogatories as follows. First, there are two Patents-in-Suit with more than twenty
`
`asserted claims. As reflected by Defendants’ request that Merck provide responses for “any
`
`claim . . . entitled to a priority date earlier than the filing date of the Patents-in-Suit” this
`
`interrogatory in fact contains dozens of interrogatories, far in excess of the fifteen joint
`
`interrogatories permitted to Defendants under the Court’s scheduling orders. Second, this
`
`interrogatory contains at least three subparts seeking (1) a narrative of facts concerning the
`
`priority date of each claim, (2) an identification of persons with discoverable information, and
`
`(3) an identification of discoverable documents. Merck further objects to this interrogatory to
`
`the extent it seeks information protected by the attorney-client privilege, attorney-work product
`
`doctrine, the common interest privilege, and/or any other applicable privilege or immunity.
`
`Merck objects to this interrogatory as it calls for subjective relevance determinations concerning
`
`persons with discoverable information and/or discoverable documents, particularly with respect
`
`to Defendants’ request that Merck identify “the three individuals employed by Merck who are
`
`most knowledgeable about the subject matter of this interrogatory.” Merck further objects to
`
`Interrogatory No. 2 as duplicative of Interrogatory No. 1, and incorporates its objections and
`
`responses to Interrogatory No. 1 herein.
`
`ME1 31736116v.1
`
`12
`
`12 of 26
`
`IPR2020-01045
`Teva Ex. 1015
`
`

`

`
`
`Subject to and without waiving the foregoing specific and general objections, Merck
`
`states as follows:
`
`The asserted claims of the ’708 patent are entitled to a priority date no later than the June
`
`24, 2003 filing date of U.S. provisional application No. 60/482,161, and that at least claims 1 and
`
`2 of the ’708 patent are entitled to a priority date no later than December 13, 2001.
`
`The asserted claims of the ’921 patent are entitled to a priority date no later than the
`
`December 16, 2005 filing date of U.S. provisional application No. 60/750,954.
`
`Discovery in this matter is ongoing, and Merck is continuing to investigate whether it
`
`will contend that one or more of the claims in any of the Patents-in-Suit is entitled to a priority
`
`date earlier than the filing dates of the Patents-in-Suit. Merck expressly reserves the right to
`
`supplement this interrogatory response.
`
`Merck further states that, based on the facts presently known to Merck, one or more of
`
`the inventors of the ’708 patent and one or more of the inventors of the ’921 patent have
`
`knowledge of facts pertaining to the priority date of the asserted claims of the Patents-in-Suit.
`
`Merck further states that additional information sought by this interrogatory can be
`
`derived or ascertained from documents that Merck will produce subject to Merck’s objections
`
`and responses herein, as well as documents that Merck will produce in response to Defendants’
`
`First Set of Joint Requests for Production of Documents and Things to Plaintiff (Nos. 1–107),
`
`subject to Merck’s objections and responses thereto. Merck will continue to supplement this
`
`interrogatory response in conjunction with the production of such documents.
`
`INTERROGATORY NO. 3:
`
`To the extent that Merck contends that any of the references identified in any of
`Defendants’ invalidity contentions for the Patents-in-Suit are not prior art under at least one of
`either 35 U.S.C. § 102(a), § 102(b), or § 102(e), identify all such references and, for each
`reference so identified, identify any evidence supporting or refuting Merck’s contention(s).
`
`ME1 31736116v.1
`
`13
`
`13 of 26
`
`IPR2020-01045
`Teva Ex. 1015
`
`

`

`
`
`RESPONSE TO INTERROGATORY NO. 3:
`
`Merck incorporates its General Objections as though fully set forth herein. Merck objects
`
`to this interrogatory as unduly burdensome and overly broad; for example, the request to identify
`
`“all facts and documents” is not a reasonable or proportionate interrogatory. Merck further
`
`objects to this interrogatory on the basis that it does not seek information relevant to any claim or
`
`defense in this case, particularly in view of the fact that Merck does not bear the burden of proof
`
`regarding invalidity. Defendants have not established a prima facie case of invalidity as to the
`
`Patents-in-Suit, and Merck’s response to this interrogatory and later supplementation thereof
`
`should not be construed as an admission or suggestion that Defendants have established a prima
`
`facie case of invalidity as to any of the asserted claims. Merck further objects to this
`
`interrogatory as vague and ambiguous as whether evidence “support[s] or refute[s] Merck’s
`
`contention(s)” requires a subjective determination that intrudes upon the attorney-work product
`
`protection. Merck further objects to this interrogatory on the grounds that it contains multiple
`
`discrete subparts within the meaning of Federal Rule of Civil Procedure 33(a)(1) and therefore
`
`constitutes multiple interrogatories, as Defendants have requested a response for “each
`
`reference” identified, and Defendants have already exceeded the fifteen joint interrogatories
`
`permitted to Defendants under the Court’s scheduling orders. Merck further objects to this
`
`interrogatory to the extent it seeks information protected by the attorney-client privilege,
`
`attorney-work product doctrine, the common interest privilege, and/or any other applicable
`
`privilege or immunity. Merck objects to this interrogatory as it calls for a legal conclusion as to
`
`whether a reference qualifies as “prior art.” This interrogatory is also premature, vague,
`
`ambiguous, and improperly assumes facts as Defendants have not served any invalidity
`
`contentions. Accordingly, no response to this interrogatory is required at this time. Merck
`
`expressly reserves the right to supplement this interrogatory response.
`
`ME1 31736116v.1
`
`14
`
`14 of 26
`
`IPR2020-01045
`Teva Ex. 1015
`
`

`

`
`
`INTERROGATORY NO. 4:
`
`Describe in detail Merck’s contentions as to the validity of the claims of the Patents-in-
`Suit in response to each invalidity contention set forth in Defendants’ invalidity contentions for
`the Patents-in-Suit, including, but not limited to, identifying each element in the claims of the
`Patents-in-Suit that Merck contends is not present in the prior art cited in Defendants’ invalidity
`contentions, describing any contention that the claims in the Patents-in-Suit are not anticipated
`by the prior art, literature, or other evidence cited or otherwise referred to in Defendants’
`invalidity contentions, describing any contention that the claims in the Patents-in-Suit are not
`rendered obvious by the prior art, literature, or other evidence cited or otherwise referenced in
`Defendants’ invalidity contentions, and describing any contention that the claims in the Patents-
`in-Suit are not invalid for lack of written description or enablement.
`
`RESPONSE TO INTERROGATORY NO. 4:
`
`Merck incorporates its General Objections as though fully set forth herein. Merck objects
`
`to this interrogatory on the basis that it does not seek information relevant to any claim or
`
`defense in this case, particularly in view of the fact that Merck does not bear the burden of proof
`
`regarding invalidity. Accordingly, Merck has no obligation or burden to (i) identify each
`
`element in the claims of the Patents-in-Suit that it contends is not present in the prior art cited in
`
`Defendants’ invalidity contentions, or (ii) describe any contention that the claims in the Patents-
`
`in-Suit are not invalid for lack of written description or enablement, beyond responding to the
`
`specific contentions set forth in Defendants’ invalidity contentions. Defendants have not
`
`established a prima facie case of invalidity as to the Patents-in-Suit, and Merck’s response to this
`
`interrogatory and later supplementation thereof should not be construed as an admission or
`
`suggestion that Defendants have established a prima facie case of invalidity as to any of the
`
`asserted claims. Merck further objects to this interrogatory on the grounds that it contains
`
`multiple discrete subparts within the meaning of Federal Rule of Civil Procedure 33(a)(1) and
`
`therefore constitutes multiple interrogatories, as Defendants have requested a response for “each
`
`invalidity contention set forth in Defendants’ invalidity contentions,” as well as a response
`
`regarding the novelty, nonobviousness, written description, and enablement of the claims of the
`
`ME1 31736116v.1
`
`15
`
`15 of 26
`
`IPR2020-01045
`Teva Ex. 1015
`
`

`

`
`
`Patents-in-Suit, and Defendants have already exceeded the fifteen joint interrogatories permitted
`
`to Defendants under the Court’s scheduling orders. Merck further objects to this interrogatory to
`
`the extent it seeks information protected by the attorney-client privilege, attorney-work product
`
`doctrine, the common interest privilege, and/or any other applicable privilege or immunity.
`
`Merck objects